OPTN

OptiNose, Inc. [OPTN] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

OPTN Stock Summary

Top 10 Correlated ETFs

OPTN


Top 10 Correlated Stocks

OPTN


In the News

01:32 22 Feb 2024 OPTN

OptiNose (OPTN) Upgraded to Buy: What Does It Mean for the Stock?

OptiNose (OPTN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

09:01 22 Feb 2024 OPTN

Optinose to Present at the 2023 Cantor Global Healthcare Conference

YARDLEY, Pa., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the 2023 Cantor Global Healthcare Conference on September 27, 2023 at 4:45 p.m. ET.

09:46 22 Feb 2024 OPTN

5 Top-Ranked Stocks With Rising P/E for Solid Returns

Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include Nektar Therapeutics (NKTR), Energous (WATT), DocuSign (DOCU), OptiNose (OPTN) and Canadian Solar (CSIQ).

10:01 22 Feb 2024 OPTN

OptiNose (OPTN) Q2 Earnings and Revenues Top Estimates

OptiNose (OPTN) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.11 per share. This compares to loss of $0.23 per share a year ago.

06:58 22 Feb 2024 OPTN

OptiNose: The Worst Has Been Avoided (Rating Upgrade)

On August 10, OptiNose, one of the leaders in the global chronic rhinosinusitis market, will publish its financial results for the 2nd quarter of 2023. OptiNose's preliminary net revenue for the second quarter of 2023 was $19.5 million, up 65.3% from the previous quarter and down 5.4% from the first quarter of 2022. On May 4, 2023, the company announced that the FDA had accepted a supplemental new drug application seeking approval for Xhance as a treatment for chronic sinusitis.

01:00 22 Feb 2024 OPTN

Optinose to Present at the Jefferies Healthcare Conference

YARDLEY, Pa., June 02, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the Jefferies Healthcare Conference on June 9, 2023 at 10:00 a.m. ET.

05:57 22 Feb 2024 OPTN

OptiNose Inc. (OPTN) Q1 2023 Earnings Call Transcript

OptiNose Inc. (NASDAQ:OPTN ) Q1 2023 Results Conference Call May 11, 2023 8:00 AM ET Company Participants Jonathan Neely - VP of IR and Business Operations Ramy Mahmoud - CEO and Director Conference Call Participants Brandon Folkes - Cantor Fitzgerald Operator Good day, and thank you for standing by. Welcome to the OptiNose's First Quarter 2023 Earnings Conference Call.

10:40 22 Feb 2024 OPTN

OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates

OptiNose (OPTN) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.31 per share a year ago.

04:30 22 Feb 2024 OPTN

Optinose Announces Reporting Date for First Quarter 2023 Financial Results

Conference Call and Webcast to be held May 11, 2023, at 8:00 a.m. Eastern Time Conference Call and Webcast to be held May 11, 2023, at 8:00 a.m. Eastern Time

04:00 22 Feb 2024 OPTN

Optinose to Present at the Needham Virtual Healthcare Conference

YARDLEY, Pa., April 12, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the Needham Virtual Healthcare Conference on April 17, 2023 at 3:45 p.m. ET.

OPTN Financial details

Company Rating
Neutral
Market Cap
153.31M
Income
-42.71M
Revenue
71.98M
Book val./share
-0.69
Cash/share
0.6
Dividend
-
Dividend %
-
Employees
141
Optionable
No
Shortable
Yes
Earnings
05 Mar 2024
P/E
-3.24
Forward P/E
-24.85
PEG
0.45
P/S
1.92
P/B
-1.78
P/C
2.48
P/FCF
-3.04
Quick Ratio
0.54
Current Ratio
0.6
Debt / Equity
-1.69
LT Debt / Equity
-
-
-
EPS (TTM)
-0.41
EPS next Y
-0.06
EPS next Q
1.57
EPS this Y
-38.19%
EPS next Y
-86.68%
EPS next 5Y
-86.68%
EPS last 5Y
-19.79%
Revenue last 5Y
60.94%
Revenue Q/Q
1.9%
EPS Q/Q
-514%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
39.45%
Inst Trans
0.76%
ROA
-42%
ROE
61%
ROC
0.46%
Gross Margin
87%
Oper. Margin
-40%
Profit Margin
-59%
Payout
-
Shs Outstand
112.31M
Shs Float
81.48M
-
-
-
-
Target Price
4.5
52W Range
0.9-2.07
52W High
-
52W Low
-
RSI
55
Rel Volume
2.24
Avg Volume
333.13K
Volume
747.18K
Perf Week
17.39%
Perf Month
19.26%
Perf Quarter
25.28%
Perf Half Y
10.43%
-
-
-
-
Beta
-0.293
-
-
Volatility
0.05%, 0.07%
Prev Close
11.25%
Price
1.4908
Change
9.62%

OPTN Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.180.831.021.310.89
Net income per share
-2.68-2.6-2.04-1.44-0.89
Operating cash flow per share
-2.31-2.17-1.79-1.35-0.79
Free cash flow per share
-2.35-2.18-1.8-1.36-0.79
Cash per share
5.053.512.991.941.1
Book value per share
2.981.470.14-0.38-0.66
Tangible book value per share
2.981.470.14-0.38-0.66
Share holders equity per share
2.981.470.14-0.38-0.66
Interest debt per share
2.062.042.912.581.72
Market cap
246.55M386.11M199.86M92.1M158.92M
Enterprise value
118.06M313.5M180.91M112.3M195.84M
P/E ratio
-2.31-3.54-2.03-1.13-2.08
Price to sales ratio
34.911.154.071.232.08
POCF ratio
-2.69-4.25-2.32-1.2-2.35
PFCF ratio
-2.64-4.23-2.3-1.19-2.35
P/B Ratio
2.086.2729.44-4.23-2.81
PTB ratio
2.086.2729.44-4.23-2.81
EV to sales
16.719.053.681.52.57
Enterprise value over EBITDA
-1.18-3.28-2.07-1.69-3.5
EV to operating cash flow
-1.29-3.45-2.1-1.46-2.89
EV to free cash flow
-1.26-3.43-2.09-1.46-2.89
Earnings yield
-0.43-0.28-0.49-0.89-0.48
Free cash flow yield
-0.38-0.24-0.43-0.84-0.43
Debt to equity
0.611.2318.76-6-2.32
Debt to assets
0.330.440.670.790.91
Net debt to EBITDA
1.280.760.22-0.3-0.66
Current ratio
7.824.072.762.710.53
Interest coverage
-10.86-9.93-6.71-4.16-3.32
Income quality
0.860.830.860.930.9
Dividend Yield
00000
Payout ratio
0-0.01-0.0100
Sales general and administrative to revenue
13.530000
Research and developement to revenue
1.430.60.480.340.2
Intangibles to total assets
00000
Capex to operating cash flow
0.020.010.0100
Capex to revenue
-0.24-0.02-0.0100
Capex to depreciation
-3.14-0.5-0.38-0.26-0.12
Stock based compensation to revenue
1.210.280.210.130.12
Graham number
13.429.282.543.523.63
ROIC
-0.54-0.68-0.63-0.58-0.74
Return on tangible assets
-0.49-0.63-0.52-0.49-0.53
Graham Net
2.721.15-0.33-0.79-0.89
Working capital
175.29M111.01M91.98M101.14M-84.49M
Tangible asset value
118.61M61.58M6.79M-21.77M-56.62M
Net current asset value
102.61M36.08M-37.87M-27.46M-106.6M
Invested capital
0.611.2318.76-6-2.32
Average receivables
1.3M8.19M18.61M29.42M34.69M
Average payables
6.5M5.37M4.56M6.75M6.65M
Average inventory
4.57M5.31M6.26M10.44M10.65M
Days sales outstanding
131.84145.64173.85173.32162.37
Days payables outstanding
1.64K249.93266.42319.61208.49
Days of inventory on hand
1.64K240.21438.87472.53372.09
Receivables turnover
2.772.512.12.112.25
Payables turnover
0.221.461.371.141.75
Inventory turnover
0.221.520.830.770.98
ROE
-0.9-1.77-14.493.751.35
Capex per share
-0.04-0.01-0.0100

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.240.220.110.170.18
Net income per share
-0.18-0.18-0.170.02-0.08
Operating cash flow per share
-0.21-0.19-0.09-0.11-0.04
Free cash flow per share
-0.21-0.19-0.09-0.11-0.04
Cash per share
0.730.990.750.640.6
Book value per share
-0.88-0.6-0.66-0.62-0.69
Tangible book value per share
-0.88-0.6-0.66-0.62-0.69
Share holders equity per share
-0.88-0.6-0.66-0.62-0.69
Interest debt per share
1.611.431.211.211.21
Market cap
304.95M175.68M215.72M137.74M138.04M
Enterprise value
374.23M212.6M262.42M197.22M202.14M
P/E ratio
-5.1-2.53-2.8913.11-3.71
Price to sales ratio
15.198.4218.217.086.96
POCF ratio
-17.43-9.94-20.59-10.99-31.2
PFCF ratio
-17.42-9.93-20.59-10.92-30
P/B Ratio
-4.15-3.1-2.92-1.98-1.78
PTB ratio
-4.15-3.1-2.92-1.98-1.78
EV to sales
18.6410.1922.1510.1410.2
Enterprise value over EBITDA
-35.28-25.44-18.26-47.27-119.33
EV to operating cash flow
-21.39-12.03-25.04-15.73-45.68
EV to free cash flow
-21.37-12.02-25.04-15.63-43.93
Earnings yield
-0.05-0.1-0.090.02-0.07
Free cash flow yield
-0.06-0.1-0.05-0.09-0.03
Debt to equity
-1.78-2.32-1.77-1.88-1.69
Debt to assets
1.240.911.141.231.29
Net debt to EBITDA
-6.53-4.42-3.25-14.26-37.84
Current ratio
0.570.530.50.630.6
Interest coverage
-2.57-1.87-3.08-0.86-0.34
Income quality
1.171.170.56-4.780.48
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
0.160.140.150.050.06
Intangibles to total assets
00000
Capex to operating cash flow
0000.010.04
Capex to revenue
0000-0.01
Capex to depreciation
-0.07-0.020-0.74-1.71
Stock based compensation to revenue
0.10.070.130.080.06
Graham number
1.891.561.570.571.14
ROIC
-0.18-0.12-0.24-0.07-0.03
Return on tangible assets
-0.14-0.12-0.160.02-0.09
Graham Net
-1.11-0.8-0.79-0.75-0.82
Working capital
-76.86M-84.49M-82.38M-60.69M-65.36M
Tangible asset value
-73.42M-56.62M-73.79M-69.66M-77.62M
Net current asset value
-77.76M-106.6M-104.78M-72.12M-80.4M
Invested capital
-1.78-2.32-1.77-1.88-1.69
Average receivables
26.19M30.27M25.46M19.55M21.75M
Average payables
9.12M6.85M5.77M6.36M5.74M
Average inventory
10.69M9.93M8.87M8.02M7.89M
Days sales outstanding
119.31146.43129102.3797.04
Days payables outstanding
355.89159.74329.4226.91202.49
Days of inventory on hand
441.11285.1438.02270.67325.33
Receivables turnover
0.750.610.70.880.93
Payables turnover
0.250.560.270.40.44
Inventory turnover
0.20.320.210.330.28
ROE
0.20.310.25-0.040.12
Capex per share
00000

OPTN Frequently Asked Questions

What is OptiNose, Inc. stock symbol ?

OptiNose, Inc. is a US stock , located in Yardley of Pa and trading under the symbol OPTN

Is OptiNose, Inc. buy or a sell ?

2 stock analysts have 2 predictions with a medium analyst target price of $4.5. The lowest prediction is $4 and the highest is $5

What is OPTN stock prediction ?

What is OptiNose, Inc. stock quote today ?

OptiNose, Inc. stock price is $1.4908 today.

Is OptiNose, Inc. stock public?

Yes, OptiNose, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap